ScholarIQanswers from OpenAlex & ORCID
Markku Miettinen
ResearcherPublications, citations & collaboration network
Markku Miettinen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Markku Miettinen have?
ScholarIQindexed works
Markku Miettinen has 902 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Markku Miettinen have?
ScholarIQcitation count
Markku Miettinen has 60,048 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Markku Miettinen?
ScholarIQh-index
Markku Miettinen has an h-index of 123 in OpenAlex.
What is the i10-index of Markku Miettinen?
ScholarIQi10-index
Markku Miettinen has an i10-index of 461 in OpenAlex.
What is the ORCID of Markku Miettinen?
ScholarIQorcid
The ORCID for Markku Miettinen is on the source record.
What is the OpenAlex record for Markku Miettinen?
ScholarIQopenalex
The OpenAlex for Markku Miettinen is on the source record.
What are the most-cited papers on Markku Miettinen?
ScholarIQmost cited works
Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity
Andrew L. Folpe, Julie C. Fanburg–Smith, Steven D. Billings, Michele Bisceglia, Franco Bertoni, Justin Y. Cho, Michael J. Econs, Carrie Y. Inwards, Suzanne M. Jan de Beur, Thomas Mentzel, Elizabeth A. Montgomery, Michal Michal, Markku Miettinen, Stacey E. Mills, John D. Reith, John X. OʼConnell, Andrew E. Rosenberg, Brian P. Rubin, Donald E. Sweet, Tuyethoa N. Vinh, Lester E. Wold, Brett M. Wehrli, Kenneth E. White, Richard J. Zaino, Sharon W. Weiss
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview
Markku Miettinen, Cristina R. Antonescu, Christopher D.�M. Fletcher, AeRang Kim, Alexander J. Lazar, Martha Quezado, Karlyne M. Reilly, Anat Stemmer‐Rachamimov, Douglas R. Stewart, David Viskochil, Brigitte C. Widemann, Arie Perry
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Hedy L. Kindler, Nofisat Ismaila, Samuel G. Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Jones, Markku Miettinen, Harvey I. Pass, Andreas Rimner, Valerie W. Rusch, Daniel H. Sterman, Anish Thomas, Raffit Hassan
Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma
Anthony J. Gill, Ondřej Hes, Thomas Papathomas, Monika Šedivcová, Puay Hoon Tan, Abbas Agaimy, Per Arne Andresen, Andrew Kedziora, Adele Clarkson, Christopher W. Toon, Loretta Sioson, Nicole Watson, Angela Chou, Julie Paik, Roderick Clifton‐Bligh, Bruce G. Robinson, Diana E. Benn, Kirsten Hills, Fiona Maclean, Nicolasine D. Niemeijer, Ljiljana Vlatkovic, Arndt Hartmann, Eleonora P.M. Corssmit, Geert J.L.H. van Leenders, Christopher G. Przybycin, Jesse K. McKenney, Cristina Magi‐Galluzzi, Aslı Yilmaz, Darryl C W Yu, Katherine D. Nicoll, Jim Yong, Mathilde Sibony, Evgeny Yakirevich, Stewart Fleming, C.W. Chow, Markku Miettinen, Michal Michal, Kiril Trpkov
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan, Andrew C. Miller, Elad Sharon, Anish Thomas, James C. Reynolds, Alexander Ling, Robert J. Kreitman, Markku Miettinen, Seth M. Steinberg, Daniel H. Fowler, Ira Pastan